CHAPTER 125 — REFERENCES

57. Adam R, Dehury V, Pascal G, et al. Rescure surgery for unresectable colorec-
tal liver metastases downstaged by chemohyperthermia: a model to predict long-


60. Van Cutsem E, Rivero F, Bern S, et al. Safety and efficacy of first-line beva-
cizumab with folfiex, folfoxi, and fluoropyrimidines in metastatic colorec-


62. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemother-


64. Kessner SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients under-

65. Mahfud M, Breitenstein S, El-Badry AM, et al. Impact of preoperative beva-
cizumab on complications after resection of colorectal liver metastases: case-

er Oncol 2010;11:58–47.

67. Ye LQ, Fernandez FG, Ritter J, Hitte E, et al. Cetuximab and chemother-

68. Aboia T, Schaghr M, Plasse M, et al. Liver histology and surgical outcomes af-
fter preoperative chemotherapy in patients with colorectal liver metastases treated with fluorodeoxyglucose plus oxaliplatin: in colorec-


71. Vignali L, Capussotti L, De Rosa G, et al. Liver resection for colorectal me-


75. Clancy TE, Dixon E, Peril R, et al. Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clin-


78. Auer RC, White RR, Kemeny NE, et al. Predictors of a true complete re-
sponse among disappearing liver metastases from colorectal cancer after che-